{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:01:39Z","timestamp":1780592499793,"version":"3.54.1"},"reference-count":266,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01743-9","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:23:29Z","timestamp":1775813009000},"page":"2773-2801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Severity and Outcome Measures in Seborrheic Dermatitis: A Systematic Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Sophia A.","family":"Mense","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawyeh","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Polaskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"8","key":"1743_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jamadermatol.2024.1987","volume":"160","author":"MT Polaskey","year":"2024","unstructured":"Polaskey MT, Chang CH, Daftary K, Fakhraie S, Miller CH, Chovatiya R. The global prevalence of seborrheic dermatitis: a systematic review and meta-analysis: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(8):846\u201355.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1743_CR2","first-page":"166","volume":"112","author":"NM LeFevre","year":"2025","unstructured":"LeFevre NM, Braudis K, Feigenbaum LS. Seborrheic dermatitis: diagnosis and treatment. Am Fam Physician. 2025;112(2):166\u201373.","journal-title":"Am Fam Physician"},{"issue":"1","key":"1743_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","volume":"20","author":"JH Powers 3rd","year":"2017","unstructured":"Powers JH 3rd, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, et\u00a0al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment Emerging Good Practices task force. Value Health. 2017;20(1):2\u201314.","journal-title":"Value Health"},{"issue":"5","key":"1743_CR4","first-page":"1152","volume":"159","author":"AP Townshend","year":"2008","unstructured":"Townshend AP, Chen C-M, Williams HC. How prominent are patient-reported outcomes in clinical trials of dermatological treatments? Br J Dermatol. 2008;159(5):1152\u20139.","journal-title":"Br J Dermatol"},{"issue":"22","key":"1743_CR5","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1001\/jama.2022.21022","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et\u00a0al. Guidelines for reporting outcomes in trial reports: The CONSORT-outcomes 2022 extension: the CONSORT-outcomes 2022 extension. JAMA. 2022;328(22):2252\u201364.","journal-title":"JAMA"},{"issue":"2","key":"1743_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/jdv.16854","volume":"35","author":"T Lange","year":"2021","unstructured":"Lange T, Kottner J, Weberschock T, Hahnel E, Apfelbacher C, Brandstetter S, et\u00a0al. Outcome assessment in dermatology clinical trials and Cochrane reviews: call for a dermatology-specific outcome taxonomy. J Eur Acad Dermatol Venereol. 2021;35(2):523\u201335.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1743_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","volume":"134","author":"J Schmitt","year":"2014","unstructured":"Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et\u00a0al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1743_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamadermatol.2018.1165","volume":"154","author":"K Callis Duffin","year":"2018","unstructured":"Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, et\u00a0al. Identifying a core domain set to assess psoriasis in clinical trials. JAMA Dermatol. 2018;154(10):1137\u201344.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1743_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707\u201313.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1743_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archderm.138.6.803","volume":"138","author":"SC Chen","year":"2002","unstructured":"Chen SC, Yeung J, Chren M-M. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6):803\u20137.","journal-title":"Arch Dermatol"},{"issue":"4","key":"1743_CR11","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1111\/bjd.16506","volume":"178","author":"J Kottner","year":"2018","unstructured":"Kottner J, Jacobi L, Hahnel E, Alam M, Balzer K, Beeckman D, et\u00a0al. Core outcome sets in dermatology: report from the second meeting of the international cochrane skin group core outcome set initiative. Br J Dermatol. 2018;178(4):e297\u2013e297.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1743_CR12","doi-asserted-by":"publisher","first-page":"adv00559","DOI":"10.2340\/00015555-3884","volume":"101","author":"RL Pattinson","year":"2021","unstructured":"Pattinson RL, Trialonis-Suthakharan N, Gupta S, Henry AL, Lavall\u00e9e JF, Otten M, et\u00a0al. Patient-reported outcome measures in dermatology: a systematic review. Acta Derm Venereol. 2021;101(9):adv00559.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"1743_CR13","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/sj.jid.5701142","volume":"127","author":"H Both","year":"2007","unstructured":"Both H, Essink-Bot M-L, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127(12):2726\u201339.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1743_CR14","doi-asserted-by":"publisher","first-page":"e0331030","DOI":"10.1371\/journal.pone.0331030","volume":"20","author":"G Ta\u015f Aygar","year":"2025","unstructured":"Ta\u015f Aygar G, Karata\u015f H, Kaya E, Borazan N\u015e, Kartal SP. The psychosocial dimensions of seborrheic dermatitis: a cross-sectional study on anxiety, personality, and quality of life. PLoS ONE. 2025;20(8):e0331030.","journal-title":"PLoS ONE"},{"issue":"3","key":"1743_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8019.2009.01231.x","volume":"22","author":"SJ Grekin","year":"2009","unstructured":"Grekin SJ, Ellis CN. Evaluating the severity of dermatologic disorders. Dermatol Ther. 2009;22(3):191\u20138.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1743_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.det.2005.05.004","volume":"23","author":"MA Gupta","year":"2005","unstructured":"Gupta MA, Johnson AM, Chren M-M. Evaluating clinical rating scales for evidence-based dermatology: some basic concepts. Dermatol Clin. 2005;23(4):703\u20136.","journal-title":"Dermatol Clin"},{"issue":"8","key":"1743_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1046\/j.1365-4362.2003.01981.x","volume":"42","author":"R Koca","year":"2003","unstructured":"Koca R, Altinyazar HC, E\u015ft\u00fcrk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42(8):632\u20135.","journal-title":"Int J Dermatol"},{"key":"1743_CR18","doi-asserted-by":"publisher","unstructured":"A new proposed severity score for seborrheic dermatitis of the face: SEborrheic Dermatitis Area and Severity Index (SEDASI). J Am Acad Dermatol. 2017;76(6):AB18. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.088","DOI":"10.1016\/j.jaad.2017.04.088"},{"issue":"10","key":"1743_CR19","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jid.2017.05.020","volume":"137","author":"D Schoch","year":"2017","unstructured":"Schoch D, Sommer R, Augustin M, St\u00e4nder S, Blome C. Patient-reported outcome measures in pruritus: a systematic review of measurement properties. J Invest Dermatol. 2017;137(10):2069\u201377.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1743_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/jdv.13214","volume":"30","author":"F Fritz","year":"2016","unstructured":"Fritz F, Blome C, Augustin M, Koch R, St\u00e4nder S. Differences in patient and physician assessment of a dynamic patient reported outcome tool for chronic pruritus. J Eur Acad Dermatol Venereol. 2016;30(6):962\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1743_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"372","key":"1743_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.","journal-title":"BMJ"},{"key":"1743_CR23","volume-title":"JBI Manual for Evidence Synthesis JBI","author":"Z Munn","year":"2020","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. systematic reviews of prevalence and incidence. In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis JBI. Australia: JBI Adelaide SA; 2020."},{"issue":"5","key":"1743_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT, et\u00a0al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO Extension. JAMA. 2018;319(5):483\u201394.","journal-title":"JAMA"},{"issue":"23","key":"1743_CR25","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et\u00a0al. Guidelines for reporting outcomes in trial protocols: the SPIRIT-outcomes 2022 extension: the SPIRIT-outcomes 2022 extension. JAMA. 2022;328(23):2345\u201356.","journal-title":"JAMA"},{"issue":"2","key":"1743_CR26","doi-asserted-by":"publisher","first-page":"s156","DOI":"10.25251\/skin.7.supp.156","volume":"7","author":"E Graber","year":"2023","unstructured":"Graber E, Baldwin H, Harper J, Stein Gold L, Alexis A, Fried R, et\u00a0al. Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular acne vulgaris (AV) administered sarecycline in community practices across the US: PROSES study analysis by gender and age. SKIN J Cutan Med. 2023;7(2):s156.","journal-title":"SKIN J Cutan Med."},{"key":"1743_CR27","unstructured":"Validity of Outcome Measures. Canadian Agency for Drugs and Technologies in Health; 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554824\/."},{"issue":"3","key":"1743_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et\u00a0al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839\u201346.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1743_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et\u00a0al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1743_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2340\/00015555-1265","volume":"92","author":"A Reich","year":"2012","unstructured":"Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et\u00a0al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497\u2013501.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1743_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archderm.1951.01570070044007","volume":"64","author":"WN Slinger","year":"1951","unstructured":"Slinger WN, Hubbard DM. Treatment of seborrheic dermatitis with a shampoo containing selenium disulfide. AMA Arch Derm Syphilol. 1951;64(1):41\u20138.","journal-title":"AMA Arch Derm Syphilol"},{"issue":"6","key":"1743_CR32","first-page":"68","volume":"72","author":"BL Snyder","year":"1969","unstructured":"Snyder BL. A double blind evaluation of fluocinolone acetonide solution in the treatment of eborrheic dermatitis of the face. Pa Med. 1969;72(6):68\u20139.","journal-title":"Pa Med"},{"issue":"5","key":"1743_CR33","first-page":"765","volume":"15","author":"T Fredriksson","year":"1975","unstructured":"Fredriksson T. Treatment of seborrheic dermatitis: double blind studies comparing dexamethasone 0.012% and fluocinolone acetonide 0.01%. Cutis. 1975;15(5):765\u20138.","journal-title":"Cutis"},{"issue":"5","key":"1743_CR34","first-page":"607","volume":"26","author":"L Gip","year":"1979","unstructured":"Gip L. A study to compare the efficacy of hydrocortisone 17-butyrate (Locoid\u00ae) 0.1% scale lotion and betamethasone 17-valerate (Betnovate\u00ae) 0.1% lotion in the treatment of seborrhoeic dermatitis of the scalp. Curr Ther Res Clin Exp. 1979;26(5):607\u201310.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"1743_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2230.1980.tb01665.x","volume":"5","author":"NK Veien","year":"1980","unstructured":"Veien NK, Pilgaard CE, Gade M. Seborrhoeic dermatitis of the scalp treated with a tar\/zinc pyrithione shampoo. Clin Exp Dermatol. 1980;5(1):53\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1743_CR36","first-page":"313","volume":"20","author":"K Ludvigsen","year":"1983","unstructured":"Ludvigsen K. Treatment of seborrhoeic dermatitis of the scalp. Report of a double-blind comparative trial of hydrocortisone 17-butyrate 0.1% lotion (locoid) and betamethasone 17,21-Dipropionate 0.05% Lotion (Diproderm). Clin Trials J. 1983;20(6):313\u20138.","journal-title":"Clin Trials J"},{"issue":"1","key":"1743_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1742-1241.1985.tb07765.x","volume":"39","author":"T Fredriksson","year":"1985","unstructured":"Fredriksson T. Controlled comparison of clinitar shampoo and selsun shampoo in the treatment of seborrhoeic dermatitis of the scalp. Br J Clin Pract. 1985;39(1):25\u20138.","journal-title":"Br J Clin Pract"},{"issue":"5 Pt 1","key":"1743_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0190-9622(85)70107-7","volume":"12","author":"RB Skinner Jr","year":"1985","unstructured":"Skinner RB Jr, Noah PW, Taylor RM, Zanolli MD, West S, Guin JD, et\u00a0al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol. 1985;12(5 Pt 1):852\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6512","key":"1743_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/bmj.292.6512.28","volume":"292","author":"J Boyle","year":"1986","unstructured":"Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J. 1986;292(6512):282\u2013328.","journal-title":"Br Med J"},{"issue":"3","key":"1743_CR40","first-page":"577","volume":"46","author":"RC Cornell","year":"1989","unstructured":"Cornell RC, Ellis CN. Comparison of the efficacy and safety of amcinonide lotion 0.1% with those of betamethasone valerate lotion 0.1% in patients with seborrheic dermatitis. Curr Ther Res Clin Exp. 1989;46(3):577\u201386.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1743_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2133.1987.tb05814.x","volume":"116","author":"MM Carr","year":"1987","unstructured":"Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol. 1987;116(2):213\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1743_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2133.1987.tb05815.x","volume":"116","author":"CA Green","year":"1987","unstructured":"Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987;116(2):217\u201321.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1743_CR43","first-page":"67","volume":"40","author":"M Shohat","year":"1987","unstructured":"Shohat M, Mimouni M, Varsano I. Efficacy of topical application of glucocorticosteroids compared with eosin in infants with seborrheic dermatitis. Cutis. 1987;40(1):67\u20138.","journal-title":"Cutis"},{"issue":"1","key":"1743_CR44","first-page":"69","volume":"42","author":"J Faergemann","year":"1988","unstructured":"Faergemann J. Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a double-blind study. Cutis. 1988;42(1):69\u201371.","journal-title":"Cutis"},{"key":"1743_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/central\/CN-00176789\/full","author":"Y Lynfield","year":"1988","unstructured":"Lynfield Y, Cornell RC, Horwitz SN, Huntley AC, Millikan LE. Amcinonide lotion 0.1% in the treatment of patients with seborrheic dermatitis of the scalp and\/or other hairy areas. Curr Ther Res Clin Exp. 1988. https:\/\/doi.org\/10.1002\/central\/CN-00176789\/full.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1743_CR46","first-page":"109","volume":"7","author":"L Massone","year":"1988","unstructured":"Massone L, Borghi S, Pestarino A, Piccini R, Solari G, Casini LM, et\u00a0al. Seborrheic dermatitis in otherwise healthy patients and in patients with lymphadenopathy syndrome\/AIDS-related complex: treatment with 1% bifonazole cream. Chemioterapia. 1988;7(2):109\u201312.","journal-title":"Chemioterapia"},{"issue":"51","key":"1743_CR47","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0190-9622(88)70244-3","volume":"19","author":"JD Stratigos","year":"1988","unstructured":"Stratigos JD, Antoniou C, Katsambas A, B\u00f6hler K, Fritsch P, Schm\u00f6lz A, et\u00a0al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J Am Acad Dermatol. 1988;19(51):850\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1743_CR48","first-page":"260","volume":"39","author":"R Cornell","year":"1986","unstructured":"Cornell R. Atrophogenic potential of alclometasone dipropionate ointment 0.05% vs hydrocortisone ointment 1.0%. Curr Ther Res Clin Exp. 1986;39(2):260\u20138.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"1743_CR49","first-page":"128","volume":"48","author":"L Dominguez","year":"1990","unstructured":"Dominguez L, Hojyo T, Vega E, Jones ML, Peets E. Comparison of the safety and efficacy of mometasone furoate cream 0.1% and clobetasone butyrate cream 0.05% in the treatment of children with a variety of dermatoses. Curr Ther Res Clin Exp. 1990;48(1):128\u201339.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1743_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2340\/0001555570171172","volume":"70","author":"J Faergemann","year":"1990","unstructured":"Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm Venereol. 1990;70(2):171\u20132.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1743_CR51","first-page":"21","volume":"8","author":"L Gip","year":"1990","unstructured":"Gip L, Lindberg L, Nordin P, Jones ML, Peets EA. Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis. Todays Ther Trends. 1990;8(3):21\u201334.","journal-title":"Todays Ther Trends"},{"issue":"1","key":"1743_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0190-9622(90)70191-J","volume":"23","author":"MC Heng","year":"1990","unstructured":"Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol. 1990;23(1):82\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1743_CR53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1365-4362.1991.tb04793.x","volume":"30","author":"GE Pi\u00e9rard","year":"1991","unstructured":"Pi\u00e9rard GE, Pi\u00e9rard-Franchimont C, Van Cutsem J, Rurangirwa A, Hoppenbrouwers ML, Schrooten P. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol. 1991;30(11):806\u20139.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1743_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/09546639209088720","volume":"3","author":"P Attila","year":"1992","unstructured":"Attila P, F\u00f6rstr\u00f6m L, Hannuksela M, Karvonen J, Lehtonen L, Salo OP. Clotrimazole\u2014Hydrocortisone, hydrocortisone and propylene glycol liniment in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 1992;3(4):185\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1743_CR55","first-page":"194","volume":"184","author":"C Cuelenaere","year":"1992","unstructured":"Cuelenaere C, De Bersaques J, Kint A. Use of topical lithium succinate in the treatment of seborrhoeic dermatitis. Dermatology. 1992;184(3):194\u20137.","journal-title":"Dermatology"},{"issue":"11","key":"1743_CR56","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s13555-024-01288-9","volume":"14","author":"MT Polaskey","year":"2024","unstructured":"Polaskey MT, Aldredge L, Heath C, Acevedo M, Chu DH, Hanna D, et\u00a0al. Patient and healthcare provider perspectives on disease burden of seborrheic dermatitis in the United States: results from a national survey. Dermatol Ther (Heidelb). 2024;14(11):3083\u201395.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1743_CR57","doi-asserted-by":"publisher","first-page":"2476576","DOI":"10.1080\/09546634.2025.2476576","volume":"36","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Chang CH, Aldredge L, Heath C, Acevedo M, Chu DH, et\u00a0al. Patient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States. J Dermatolog Treat. 2025;36(1):2476576.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1743_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/00015555-1731","volume":"94","author":"F Sampogna","year":"2014","unstructured":"Sampogna F, Linder D, Piaserico S, Altomare G, Bortune M, Calzavara-Pinton P, et\u00a0al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1743_CR59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/jdv.20321","volume":"39","author":"J Vyas","year":"2025","unstructured":"Vyas J, Johns JR, Abdelrazik Y, Ali FM, Ingram JR, Salek S, et\u00a0al. The dermatology life quality index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: a systematic review. J Eur Acad Dermatol Venereol. 2025;39(3):631\u201379.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1743_CR60","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/bjd.20765","volume":"186","author":"\u00c1 Szab\u00f3","year":"2022","unstructured":"Szab\u00f3 \u00c1, Brodszky V, Rencz F. A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-Relevant and Skindex-16. Br J Dermatol. 2022;186(3):485\u201395. https:\/\/doi.org\/10.1111\/bjd.20765.","journal-title":"Br J Dermatol."},{"issue":"1","key":"1743_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archderm.1951.01570070044007","volume":"64","author":"WN Slinger","year":"1951","unstructured":"Slinger WN, Hubbard DM. Treatment of seborrheic dermatitis with a shampoo containing selenium disulfide. AMA Arch Derm Syphilol. 1951;64(1):41\u20138. https:\/\/doi.org\/10.1001\/archderm.1951.01570070044007.","journal-title":"AMA Arch Derm Syphilol"},{"issue":"5","key":"1743_CR62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/central\/CN-01253643\/abstract","volume":"26","author":"L Gip","year":"1979","unstructured":"Gip L. A study to compare the efficacy of hydrocortisone 17-butyrate (Locoid\u00ae) 0.1% scale lotion and betamethasone 17-valerate (Betnovate\u00ae) 0.1% lotion in the treatment of seborrhoeic dermatitis of the scalp. Curr Ther Res Clin Exp. 1979;26(5):607\u201310. https:\/\/doi.org\/10.1002\/central\/CN-01253643\/abstract.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"1743_CR63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2230.1980.tb01665.x","volume":"5","author":"NK Veien","year":"1980","unstructured":"Veien NK, Pilgaard CE, Gade M. Seborrhoeic dermatitis of the scalp treated with a tar\/zinc pyrithione shampoo. Clin Exp Dermatol. 1980;5(1):53\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1980.tb01665.x.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1743_CR64","first-page":"313","volume":"20","author":"K Ludvigsen","year":"1983","unstructured":"Ludvigsen K. Treatment of seborrhoeic dermatitis of the scalp Report of a double-blind comparative trial of hydrocortisone 17-butyrate 0.1% lotion (locoid) and betamethasone 17,21-Dipropionate 0.05% Lotion (Diproderm). Clin Trials J. 1983;20(6):313\u20138.","journal-title":"Clin Trials J"},{"issue":"5 Pt 1","key":"1743_CR65","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0190-9622(85)70107-7","volume":"12","author":"RB Skinner Jr","year":"1985","unstructured":"Skinner RB Jr, Noah PW, Taylor RM, Zanolli MD, West S, Guin JD, et\u00a0al. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol. 1985;12(5 Pt 1):852\u20136. https:\/\/doi.org\/10.1016\/S0190-9622(85)70107-7.","journal-title":"J Am Acad Dermatol"},{"issue":"6512","key":"1743_CR66","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/bmj.292.6512.28-a","volume":"292","author":"J Boyle","year":"1986","unstructured":"Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J. 1986;292(6512):282\u2013328. https:\/\/doi.org\/10.1136\/bmj.292.6512.28-a.","journal-title":"Br Med J"},{"issue":"2","key":"1743_CR67","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/central\/CN-00175185","volume":"39","author":"R Cornell","year":"1986","unstructured":"Cornell R. Atrophogenic potential of alclometasone dipropionate ointment 0.05% vs hydrocortisone ointment 1.0%. Curr Ther Res Clin Exp. 1986;39(2):260\u20138. https:\/\/doi.org\/10.1002\/central\/CN-00175185.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1743_CR68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2133.1987.tb05814.x","volume":"116","author":"MM Carr","year":"1987","unstructured":"Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol. 1987;116(2):213\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.1987.tb05814.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1743_CR69","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2133.1987.tb05815.x","volume":"116","author":"CA Green","year":"1987","unstructured":"Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987;116(2):217\u201321. https:\/\/doi.org\/10.1111\/j.1365-2133.1987.tb05815.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1743_CR70","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0190-9622(88)70244-3","volume":"19","author":"JD Stratigos","year":"1988","unstructured":"Stratigos JD, Antoniou C, Katsambas A, B\u00f6hler K, Fritsch P, Schm\u00f6lz A, et\u00a0al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J Am Acad Dermatol. 1988;19(5):850\u20133. https:\/\/doi.org\/10.1016\/S0190-9622(88)70244-3.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1743_CR71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/central\/CN-00196731\/full","volume":"48","author":"L Dominguez","year":"1990","unstructured":"Dominguez L, Hojyo T, Vega E, Jones ML, Peets E. Comparison of the safety and efficacy of mometasone furoate cream 0.1% and clobetasone butyrate cream 0.05% in the treatment of children with a variety of dermatoses. Curr Ther Res Clin Exp. 1990;48(1):128\u201339. https:\/\/doi.org\/10.1002\/central\/CN-00196731\/full.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1743_CR72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2340\/0001555570171172","volume":"70","author":"J Faergemann","year":"1990","unstructured":"Faergemann J. Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm Venereol. 1990;70(2):171\u20132. https:\/\/doi.org\/10.2340\/0001555570171172.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1743_CR73","first-page":"21","volume":"8","author":"L Gip","year":"1990","unstructured":"Gip L, Lindberg L, Nordin P, Jones ML, Peets EA. Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis. Today\u2019s Ther Trends. 1990;8(3):21\u201334.","journal-title":"Today\u2019s Ther Trends"},{"issue":"1","key":"1743_CR74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0190-9622(90)70191-J","volume":"23","author":"MC Heng","year":"1990","unstructured":"Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol. 1990;23(1):82\u20136. https:\/\/doi.org\/10.1016\/0190-9622(90)70191-J.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1743_CR75","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1365-4362.1991.tb04793.x","volume":"30","author":"GE Pi\u00e9rard","year":"1991","unstructured":"Pi\u00e9rard GE, Pi\u00e9rard-Franchimont C, Van Cutsem J, Rurangirwa A, Hoppenbrouwers ML, Schrooten P. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol. 1991;30(11):806\u20139. https:\/\/doi.org\/10.1111\/j.1365-4362.1991.tb04793.x.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1743_CR76","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/central\/CN-00182058","volume":"3","author":"P Attila","year":"1992","unstructured":"Attila P, F\u00f6rstr\u00f6m L, Hannuksela M, Karvonen J, Lehtonen L, Salo OP. Clotrimazole\u2014Hydrocortisone, hydrocortisone and propylene glycol liniment in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 1992;3(4):185\u20138. https:\/\/doi.org\/10.1002\/central\/CN-00182058.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1743_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000247539","volume":"184","author":"C Cuelenaere","year":"1992","unstructured":"Cuelenaere C, De Bersaques J, Kint A. Use of topical lithium succinate in the treatment of seborrhoeic dermatitis. Dermatology. 1992;184(3):194\u20137. https:\/\/doi.org\/10.1159\/000247539.","journal-title":"Dermatology"},{"issue":"3 Pt 2","key":"1743_CR78","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/0190-9622(92)70071-M","volume":"26","author":"Efalith Multicenter Trial Group","year":"1992","unstructured":"Efalith Multicenter Trial Group. A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 1992;26(3 Pt 2):452\u20137. https:\/\/doi.org\/10.1016\/0190-9622(92)70071-M.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1743_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/09546639209088705","volume":"3","author":"R Medansky","year":"1992","unstructured":"Medansky R, Lepaw MI, Shavin JS, Zimmerman EH, Jones ML, Peets EA, et\u00a0al. Mometasone furoate cream 0.1% vs. hydrocortisone cream 1% in the treatment of seborrhoeic dermatitis. J Dermatolog Treat. 1992;3(3):125\u20138. https:\/\/doi.org\/10.3109\/09546639209088705.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1743_CR80","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000247566","volume":"184","author":"JP Ortonne","year":"1992","unstructured":"Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology. 1992;184(4):275\u201380. https:\/\/doi.org\/10.1159\/000247566.","journal-title":"Dermatology"},{"issue":"6","key":"1743_CR81","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/central\/CN-00090576","volume":"72","author":"R Segal","year":"1992","unstructured":"Segal R, David M, Ingber A, Lurie R, Sandbank M. Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis: a randomized, double-blind study. Acta Derm Venereol. 1992;72(6):454\u20135. https:\/\/doi.org\/10.1002\/central\/CN-00090576.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1743_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/central\/CN-00181341","volume":"4","author":"R Ramirez","year":"1993","unstructured":"Ramirez R, Dorton D. Double-blind placebo-controlled multicentre study of fluocinolone acetonide shampoo (FS Shampoo) in scalp seborrhoeic dermatitis. J Dermatolog Treat. 1993;4(3):135\u20137. https:\/\/doi.org\/10.1002\/central\/CN-00181341.","journal-title":"J Dermatolog Treat"},{"issue":"9\u201310","key":"1743_CR83","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1439-0507.1993.tb00776.x","volume":"36","author":"H Zienicke","year":"1993","unstructured":"Zienicke H, Korting HC, Braun-Falco O, Effendy I, Hagedorn M, Kuchmeister B, et\u00a0al. Wirksamkeit und vertraglichkeit von 1%iger bifonazol-creme und korrespondierender basiscreme beim seborrhoischen ekzem. Mycoses. 1993;36(9\u201310):325\u201331.","journal-title":"Mycoses"},{"issue":"2","key":"1743_CR84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-4362.1994.tb01546.x","volume":"33","author":"D Rigopoulos","year":"1994","unstructured":"Rigopoulos D, Katsambas A, Antoniou C, Theocharis S, Stratigos J. Facial seborrheic dermatitis treated with fluconazole 2% shampoo. Int J Dermatol. 1994;33(2):136\u20137. https:\/\/doi.org\/10.1111\/j.1365-4362.1994.tb01546.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1743_CR85","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2133.1995.tb08680.x","volume":"132","author":"RU Peter","year":"1995","unstructured":"Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132(3):441\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb08680.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1743_CR86","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/central\/CN-00170865","volume":"57","author":"K Hersle","year":"1996","unstructured":"Hersle K, Mobacken H, Nordin P. Mometasone furoate solution 0.1% compared with ketoconazole shampoo 2% for seborrheic dermatitis of the scalp. Curr Ther Res Clin Exp. 1996;57(7):516\u201322. https:\/\/doi.org\/10.1002\/central\/CN-00170865.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"1743_CR87","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1525-1470.1996.tb01425.x","volume":"13","author":"A Zeharia","year":"1996","unstructured":"Zeharia A, Mimouni M, Fogel D. Treatment with bifonazole shampoo for scalp seborrhea in infants and young children. Pediatr Dermatol. 1996;13(2):151\u20133. https:\/\/doi.org\/10.1111\/j.1525-1470.1996.tb01425.x.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"1743_CR88","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1468-3083.1998.tb00938.x","volume":"10","author":"T Pari","year":"1998","unstructured":"Pari T, Pulimood S, Jacob M, George S, Jeyaseelan KT L. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol. 1998;10(1):89\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1743_CR89","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/09546639809160547","volume":"9","author":"D Shuttleworth","year":"1998","unstructured":"Shuttleworth D, Squire R, Boorman G, Goode K. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%; Nizoral\u00ae) for the control of dandruff\/seborrhoeic dermatitis. J Dermatolog Treat. 1998;9(3):157\u201362. https:\/\/doi.org\/10.3109\/09546639809160547.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1743_CR90","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/09546639809160702","volume":"9","author":"AV Veen","year":"1998","unstructured":"Veen AV, Prevoo R, Velders A, Jagtman B, van Niel J, Stolz E. Betamethasone-17-valerate compared with ketoconazole for topical treatment of seborrhoeic dermatitis of the scalp in adults. Results of a Dutch multicentre study. J Dermatolog Treat. 1998;9(4):239\u201345. https:\/\/doi.org\/10.3109\/09546639809160702.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1743_CR91","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/09546639909056025","volume":"10","author":"D Davies","year":"1999","unstructured":"Davies D, Boorman GC, Shuttleworth D. Comparative efficacy of shampoos containing coal tar (4.0% w\/w; TarmedTM), coal tar (4.0% w\/w) plus ciclopirox olamine (1.0% w\/w; TarmedTM AF) and ketoconazole (2.0% w\/w; NizoralTM) for the treatment of dandruff\/seborrhoeic dermatitis. J Dermatolog Treat. 1999;10(3):177\u201383. https:\/\/doi.org\/10.3109\/09546639909056025.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1743_CR92","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/09546639909055904","volume":"10","author":"D Vardy","year":"1999","unstructured":"Vardy D, Cohen A, Tchetov T, Medvedovsky E, Biton A. A double-blind, placebo-controlled trial of anAloe vera (A. barbadensis)emulsion in the treatment of seborrheic dermatitis. J Dermatolog Treat. 1999;10(1):7\u201311. https:\/\/doi.org\/10.3109\/09546639909055904.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1743_CR93","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1046\/j.1365-2133.2000.03828.x","volume":"143","author":"D Pirkhammer","year":"2000","unstructured":"Pirkhammer D, Seeber A, H\u00f6nigsmann H, Tanew A. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol. 2000;143(5):964\u20138. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03828.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1743_CR94","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1046\/j.1365-4362.2000.00986-3.x","volume":"39","author":"A Shemer","year":"2000","unstructured":"Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol. 2000;39(7):532\u20134. https:\/\/doi.org\/10.1046\/j.1365-4362.2000.00986-3.x.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1743_CR95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/09546630050517441","volume":"11","author":"DA Vardy","year":"2000","unstructured":"Vardy DA, Zvulunov A, Tchetov T, Biton A, Rosenman D. A double-blind, placebo-controlled trial of a ciclopirox olamine 1% shampoo for the treatment of scalp seborrheic dermatitis. J Dermatolog Treat. 2000;11(2):73\u20137. https:\/\/doi.org\/10.1080\/09546630050517441.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"1743_CR96","first-page":"306","volume":"6","author":"NS Al-Waili","year":"2001","unstructured":"Al-Waili NS. Therapeutic and prophylactic effects of crude honey on chronic seborrheic dermatitis and dandruff. Eur J Med Res. 2001;6(7):306\u20138.","journal-title":"Eur J Med Res"},{"issue":"5","key":"1743_CR97","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1046\/j.1365-2133.2001.04194.x","volume":"144","author":"P Dupuy","year":"2001","unstructured":"Dupuy P, Maurette C, Amoric JC, Chosidow O, Study Investigator Group. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol. 2001;144(5):1033\u20137. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04194.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1743_CR98","first-page":"492","volume":"50","author":"AC Iudica","year":"2001","unstructured":"Iudica AC. Does treatment with topical metronidazole improve seborrheic dermatitis? J Fam Pract. 2001;50(6):492.","journal-title":"J Fam Pract"},{"issue":"1","key":"1743_CR99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000051582","volume":"202","author":"D Parsad","year":"2001","unstructured":"Parsad D, Pandhi R, Negi KS, Kumar B. Topical metronidazole in seborrheic dermatitis\u2014A double-blind study. Dermatology. 2001;202(1):35\u20137. https:\/\/doi.org\/10.1159\/000051582.","journal-title":"Dermatology"},{"issue":"2","key":"1743_CR100","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000051628","volume":"202","author":"C Pi\u00e9rard-Franchimont","year":"2001","unstructured":"Pi\u00e9rard-Franchimont C, Pi\u00e9rard GE, Arrese JE, De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology. 2001;202(2):171\u20136. https:\/\/doi.org\/10.1159\/000051628.","journal-title":"Dermatology"},{"issue":"4","key":"1743_CR101","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1046\/j.1365-2133.2001.04144.x","volume":"144","author":"E Scaparro","year":"2001","unstructured":"Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 2001;144(4):854\u20137. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04144.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1743_CR102","first-page":"181","volume":"137","author":"RBM Caputo","year":"2002","unstructured":"Caputo RBM. Itraconazole: new horizons. G Ital Dermatol Venereol. 2002;137(3):181\u20137.","journal-title":"G Ital Dermatol Venereol"},{"issue":"11","key":"1743_CR103","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1365-4362.2002.01672.x","volume":"41","author":"N Cassano","year":"2002","unstructured":"Cassano N, Amoruso A, Loconsole F, Vena GA. Oral terbinafine for the treatment of seborrheic dermatitis in adults: oral terbinafine in seborrhoeic dermatitis. Int J Dermatol. 2002;41(11):821\u20132. https:\/\/doi.org\/10.1046\/j.1365-4362.2002.01672.x.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1743_CR104","first-page":"549","volume":"12","author":"B Dreno","year":"2002","unstructured":"Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur J Dermatol. 2002;12(6):549\u201352.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"1743_CR105","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1034\/j.1600-0846.2002.20337.x","volume":"8","author":"MA Perkins","year":"2002","unstructured":"Perkins MA, Cardin CW, Osterhues MA, Robinson MK. A non-invasive tape absorption method for recovery of inflammatory mediators to differentiate normal from compromised scalp conditions: non-invasive assesment of scalp conditions. Skin Res Technol. 2002;8(3):187\u201393. https:\/\/doi.org\/10.1034\/j.1600-0846.2002.20337.x.","journal-title":"Skin Res Technol"},{"issue":"4","key":"1743_CR106","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000063382","volume":"204","author":"C Pi\u00e9rard-Franchimont","year":"2002","unstructured":"Pi\u00e9rard-Franchimont C, Pi\u00e9rard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology. 2002;204(4):344\u20137. https:\/\/doi.org\/10.1159\/000063382.","journal-title":"Dermatology"},{"issue":"6","key":"1743_CR107","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000066452","volume":"15","author":"C Pi\u00e9rard-Franchimont","year":"2002","unstructured":"Pi\u00e9rard-Franchimont C, Goffin V, Decroix J, Pi\u00e9rard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002;15(6):434\u201341. https:\/\/doi.org\/10.1159\/000066452.","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"issue":"1","key":"1743_CR108","first-page":"59","volume":"7","author":"SA Smith","year":"2002","unstructured":"Smith SA, Baker AE, Williams JH. Effective treatment of seborrheic dermatitis using a low dose, oral homeopathic medication consisting of potassium bromide, sodium bromide, nickel sulfate, and sodium chloride in a double-blind, placebo-controlled study. Altern Med Rev. 2002;7(1):59\u201367.","journal-title":"Altern Med Rev"},{"issue":"2","key":"1743_CR109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/095466302317584395","volume":"13","author":"RA Squire","year":"2002","unstructured":"Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff\/seborrhoeic dermatitis. J Dermatolog Treat. 2002;13(2):51\u201360. https:\/\/doi.org\/10.1080\/095466302317584395.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1743_CR110","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s15010-002-2196-9","volume":"30","author":"A Unholzer","year":"2002","unstructured":"Unholzer A, Varigos G, Nicholls D, Schinzel S, Nietsch K-H, Ulbricht H, et\u00a0al. Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. Infection. 2002;30(6):373\u20136. https:\/\/doi.org\/10.1007\/s15010-002-2196-9.","journal-title":"Infection"},{"issue":"3","key":"1743_CR111","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00044011-200222030-00003","volume":"22","author":"A Unholzer","year":"2002","unstructured":"Unholzer A, Schinzel S, Nietsch K-H, Jung GE, Korting HC. Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis: a double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin Drug Investig. 2002;22(3):167\u201372. https:\/\/doi.org\/10.2165\/00044011-200222030-00003.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"1743_CR112","first-page":"504","volume":"52","author":"Z Zaidi","year":"2002","unstructured":"Zaidi Z, Wahid Z, Cochinwala R, Soomro M, Qureishi A. Correlation of the density of yeast Malassezia with the clinical severity of seborrhoeic dermatitis. J Pak Med Assoc. 2002;52(11):504\u20136.","journal-title":"J Pak Med Assoc"},{"issue":"Suppl 1(S1)","key":"1743_CR113","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1365-4362.42.s1.5.x","volume":"42","author":"R Aly","year":"2003","unstructured":"Aly R, Katz HI, Kempers SE, Lookingbill DP, Lowe N, Menter A, et\u00a0al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol. 2003;42(Suppl 1(S1)):19\u201322. https:\/\/doi.org\/10.1046\/j.1365-4362.42.s1.5.x.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1743_CR114","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1046\/j.1365-2133.2003.05383.x","volume":"148","author":"TJ Braza","year":"2003","unstructured":"Braza TJ, DiCarlo JB, Soon SL, McCall CO. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol. 2003;148(6):1242\u20134. https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05383.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1743_CR115","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000068904","volume":"206","author":"O Chosidow","year":"2003","unstructured":"Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology. 2003;206(3):233\u201340. https:\/\/doi.org\/10.1159\/000068904.","journal-title":"Dermatology"},{"issue":"6","key":"1743_CR116","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1046\/j.1365-2133.2003.05328.x","volume":"148","author":"B Dreno","year":"2003","unstructured":"Dreno B, Chosidow O, Revuz J, Moyse D, Study Investigator Group. Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol. 2003;148(6):1230\u20136. https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05328.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1743_CR117","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/archderm.139.3.318","volume":"139","author":"P Foley","year":"2003","unstructured":"Foley P, Zuo Y, Plunkett A, Merlin K, Marks R. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003;139(3):318\u201322. https:\/\/doi.org\/10.1001\/archderm.139.3.318.","journal-title":"Arch Dermatol"},{"issue":"8","key":"1743_CR118","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1046\/j.1365-4362.2003.01981.x","volume":"42","author":"R Koca","year":"2003","unstructured":"Koca R, Altinyazar HC, E\u015ft\u00fcrk E. Is topical Metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42(8):632\u20135. https:\/\/doi.org\/10.1046\/j.1365-4362.2003.01981.x.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1743_CR119","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1067\/mjd.2003.450","volume":"49","author":"A Meshkinpour","year":"2003","unstructured":"Meshkinpour A, Sun J, Weinstein G. An open pilot study using Tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003;49(1):145\u20137. https:\/\/doi.org\/10.1067\/mjd.2003.450.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1743_CR120","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1185\/030079903125001875","volume":"19","author":"M Milani","year":"2003","unstructured":"Milani M, Antonio Di Molfetta S, Gramazio R, Fiorella C, Frisario C, Fuzio E, et\u00a0al. Efficacy of Betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr Med Res Opin. 2003;19(4):342\u20135. https:\/\/doi.org\/10.1185\/030079903125001875.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1(S1)","key":"1743_CR121","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1461-1244.2004.02382.x","volume":"43","author":"D Abeck","year":"2004","unstructured":"Abeck D, Loprox Shampoo Dosing Study Group. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol. 2004;43(Suppl 1(S1)):13\u20136. https:\/\/doi.org\/10.1111\/j.1461-1244.2004.02382.x.","journal-title":"Int J Dermatol"},{"issue":"S1","key":"1743_CR122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1461-1244.2004.02381.x","volume":"43","author":"P Altmeyer","year":"2004","unstructured":"Altmeyer P, Hoffmann K. Efficacy of different concentrations of Ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol. 2004;43(S1):9\u201312. https:\/\/doi.org\/10.1111\/j.1461-1244.2004.02381.x.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1743_CR123","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-4632.2004.02123.x","volume":"43","author":"V Baysal","year":"2004","unstructured":"Baysal V, Yildirim M, Ozcanli C, Ceyhan AM. Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. Int J Dermatol. 2004;43(1):63\u20136. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02123.x.","journal-title":"Int J Dermatol"},{"issue":"Suppl 1(S1)","key":"1743_CR124","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1461-1244.2004.02409.x","volume":"43","author":"M Lebwohl","year":"2004","unstructured":"Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol. 2004;43(Suppl 1(S1)):17\u201320. https:\/\/doi.org\/10.1111\/j.1461-1244.2004.02409.x.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1743_CR125","first-page":"149","volume":"139","author":"A Patrizi","year":"2004","unstructured":"Patrizi A, Marzaduri S, Neri I, Medri M. Clinical study of the efficacy of frequent shampoo use for two childhood scalp conditions: cradle cap and atopic dandruff. G Ital Dermatol Venereol. 2004;139(2):149\u201353.","journal-title":"G Ital Dermatol Venereol"},{"issue":"5\u20136","key":"1743_CR126","first-page":"191","volume":"30","author":"E Rallis","year":"2004","unstructured":"Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004;30(5\u20136):191\u20135.","journal-title":"Drugs Exp Clin Res"},{"issue":"5","key":"1743_CR127","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1365-2133.2004.06208.x","volume":"151","author":"D Rigopoulos","year":"2004","unstructured":"Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151(5):1071\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06208.x.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"1743_CR128","first-page":"S68","volume":"87","author":"S Wannanukul","year":"2004","unstructured":"Wannanukul S, Chiabunkana J. Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis. J Med Assoc Thai. 2004;87(Suppl 2):S68-71.","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"1743_CR129","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1346-8138.2005.tb00708.x","volume":"32","author":"K G\u00fcnd\u00fcz","year":"2005","unstructured":"G\u00fcnd\u00fcz K, Inanir I, Sacar H. Efficacy of terbinafine 1% cream on seborrhoeic dermatitis. J Dermatol. 2005;32(1):22\u20135. https:\/\/doi.org\/10.1111\/j.1346-8138.2005.tb00708.x.","journal-title":"J Dermatol"},{"issue":"2","key":"1743_CR130","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1468-3083.2005.01090.x","volume":"19","author":"O Kose","year":"2005","unstructured":"Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial. J Eur Acad Dermatol Venereol. 2005;19(2):172\u20135. https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01090.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1743_CR131","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archderm.141.1.47","volume":"141","author":"S Shuster","year":"2005","unstructured":"Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005;141(1):47\u201352. https:\/\/doi.org\/10.1001\/archderm.141.1.47.","journal-title":"Arch Dermatol"},{"issue":"6","key":"1743_CR132","first-page":"271","volume":"22","author":"W Silny","year":"2005","unstructured":"Silny W, Chomczy\u0144ski P, Danczak-Pazdrowska MC-OA, Silny P. Efficacy and safety of cis-trans-1,4-cyclohaxanediol gel in the case of adult patients with rosacea, seborrheic dermatitis and facial dermatitis. Postepy Dermatol Alergol. 2005;22(6):271\u20137.","journal-title":"Postepy Dermatol Alergol"},{"issue":"4","key":"1743_CR133","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/039463200501800418","volume":"18","author":"GA Vena","year":"2005","unstructured":"Vena GA, Micali G, Santoianni P, Cassano N, Peruzzi E. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J Immunopathol Pharmacol. 2005;18(4):745\u201353. https:\/\/doi.org\/10.1177\/039463200501800418.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1743_CR134","unstructured":"Danmark A. Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% nicotinamide combined with either 0%, 0.5% or 1.0% GMCY with placebo cream. EU Clinical Trials Register. 2006. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-005637-37."},{"issue":"7","key":"1743_CR135","first-page":"646","volume":"5","author":"B Elewski","year":"2006","unstructured":"Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006;5(7):646\u201350.","journal-title":"J Drugs Dermatol"},{"key":"1743_CR136","unstructured":"Intendis GmbH. A double-blind, randomized, vehicle-controlled, 6-week exploratory multicenter pilot study of the efficacy and safety of Azelaic Acid (AzA) 15% gel in the topical treatment of mild to moderate seborrheic dermatitis of the face. EU Clinical Trials Register. 2006. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-002060-26."},{"issue":"5","key":"1743_CR137","first-page":"558","volume":"16","author":"G Lorette","year":"2006","unstructured":"Lorette G, Ermosilla V. Clinical efficacy of a new ciclopiroxolamine\/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. Eur J Dermatol: EJD. 2006;16(5):558\u201364.","journal-title":"Eur J Dermatol: EJD"},{"key":"1743_CR138","unstructured":"Novartis Pharma Services AG. A multicenter, randomized, double-blind, two-arm, vehicle-controlled, parallel-group, two stage study to evaluate and demonstrate the efficacy and to evaluate the safety of pimecrolimus 1% cream in the treatment of seborrhoeic dermatitis in patients 12 years of age and older. EU Clinical Trials Register. 2006. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-003984-30."},{"issue":"3","key":"1743_CR139","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1468-3083.2006.01927.x","volume":"21","author":"D Seckin","year":"2007","unstructured":"Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007;21(3):345\u201350. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01927.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1743_CR140","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4103\/0378-6323.26745","volume":"72","author":"AH Siadat","year":"2006","unstructured":"Siadat AH, Iraji F, Shahmoradi Z, Enshaieh S, Taheri A. The efficacy of 1% metronidazole gel in facial seborrheic dermatitis: a double blind study. Indian J Dermatol Venereol Leprol. 2006;72(4):266\u20139. https:\/\/doi.org\/10.4103\/0378-6323.26745.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1743_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/central\/CN-01879399\/full","author":"University of Kiel Group","year":"2006","unstructured":"University of Kiel Group. Clinical efficacy of pimecrolimus cream in seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control. Pimecrolimus vs Ketoconazole. 2006. https:\/\/doi.org\/10.1002\/central\/CN-01879399\/full.","journal-title":"Pimecrolimus vs Ketoconazole"},{"issue":"1","key":"1743_CR142","first-page":"39","volume":"48","author":"LG Zisova","year":"2006","unstructured":"Zisova LG. Fluconazole and its place in the treatment of seborrheic dermatitis\u2014New therapeutic possibilities. Folia Med (Plovdiv). 2006;48(1):39\u201345.","journal-title":"Folia Med (Plovdiv)"},{"key":"1743_CR143","unstructured":"AstionPharma. Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: a phase III randomised, multi-centre, double-blind, active comparator (ketoconazole cream 2%) and placebo controlled non-inferiority trial - ASF-1057-302. 2007. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01857081\/full."},{"key":"1743_CR144","unstructured":"AstionPharm. Efficacy and safety of ASF 1057 cream 0.5% in the treatment of seborrhoeic dermatitis: a phase III randomised, double-blind, vehicle- and placebo controlled, parallel groups, multi-centre trial. 2007. https:\/\/clinicaltrials.gov\/study\/NCT00565279?term=AREA%5BSponsorSearch%5D(COVERAGE%5BFullMatch%5DEXPANSION%5BNone%5D(%22Astion%20Pharma%20A%2FS%22))&rank=3."},{"issue":"4","key":"1743_CR145","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00128071-200708040-00005","volume":"8","author":"A Comert","year":"2007","unstructured":"Comert A, Bekiroglu N, Gurbuz O, Ergun T. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J Clin Dermatol. 2007;8(4):235\u20138. https:\/\/doi.org\/10.2165\/00128071-200708040-00005.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1743_CR146","first-page":"1001","volume":"6","author":"BE Elewski","year":"2007","unstructured":"Elewski BE, Abramovits W, Kempers S, Schlessinger J, Rosen T, Gupta AK, et\u00a0al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6(10):1001\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1743_CR147","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3346\/jkms.2007.22.5.868","volume":"22","author":"B-S Kim","year":"2007","unstructured":"Kim B-S, Kim S-H, Kim M-B, Oh C-K, Jang H-S, Kwon K-S. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22(5):868\u201372. https:\/\/doi.org\/10.3346\/jkms.2007.22.5.868.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"1743_CR148","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1684\/ejd.2007.0206","volume":"17","author":"H Ozcan","year":"2007","unstructured":"Ozcan H, Seyhan M, Yologlu S. Is metronidazole 0.75% gel effective in the treatment of seborrhoeic dermatitis? A double-blind, placebo controlled study. Eur J Dermatol. 2007;17(4):313\u20136. https:\/\/doi.org\/10.1684\/ejd.2007.0206.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1743_CR149","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000098577","volume":"214","author":"GE Pi\u00e9rard","year":"2007","unstructured":"Pi\u00e9rard GE, Ausma J, Henry F, Vroome V, Wouters L, Borgers M, et\u00a0al. A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology. 2007;214(2):162\u20139. https:\/\/doi.org\/10.1159\/000098577.","journal-title":"Dermatology"},{"issue":"2","key":"1743_CR150","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/16537150601092944","volume":"18","author":"RC Ratnavel","year":"2007","unstructured":"Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat. 2007;18(2):88\u201396. https:\/\/doi.org\/10.1080\/16537150601092944.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1743_CR151","first-page":"397","volume":"79","author":"P Reygagne","year":"2007","unstructured":"Reygagne P, Poncet M, Sidou F, Soto P. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis. 2007;79(5):397\u2013403.","journal-title":"Cutis"},{"issue":"6","key":"1743_CR152","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/central\/CN-01215763","volume":"79","author":"LJ Swinyer","year":"2007","unstructured":"Swinyer LJ, Decroix J, Langner A, Quiring JN, Blockhuys S. Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. Cutis. 2007;79(6):475\u201382. https:\/\/doi.org\/10.1002\/central\/CN-01215763.","journal-title":"Cutis"},{"issue":"2","key":"1743_CR153","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jaad.2006.11.007","volume":"57","author":"EM Warshaw","year":"2007","unstructured":"Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et\u00a0al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57(2):257\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2006.11.007.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1743_CR154","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1468-3083.2007.02404.x","volume":"22","author":"S Veraldi","year":"2008","unstructured":"Veraldi S, Menter A, Innocenti M. Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol. 2008;22(3):290\u20136. https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02404.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1743_CR155","first-page":"417","volume":"10","author":"A Shemer","year":"2008","unstructured":"Shemer A, Kaplan B, Nathansohn N, Grunwald MH, Amichai B, Trau H. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. Isr Med Assoc J. 2008;10(6):417\u20138.","journal-title":"Isr Med Assoc J"},{"issue":"6","key":"1743_CR156","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/09546630802687349","volume":"20","author":"D Cicek","year":"2009","unstructured":"Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009;20(6):344\u20139. https:\/\/doi.org\/10.3109\/09546630802687349.","journal-title":"J Dermatolog Treat"},{"issue":"6 Suppl","key":"1743_CR157","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.clindermatol.2009.09.002","volume":"27","author":"B Elewski","year":"2009","unstructured":"Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009;27(6 Suppl):S48-53. https:\/\/doi.org\/10.1016\/j.clindermatol.2009.09.002.","journal-title":"Clin Dermatol"},{"issue":"3","key":"1743_CR158","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1600-0625.2008.00834.x","volume":"18","author":"J Jensen","year":"2009","unstructured":"Jensen J, Clausen C, F\u00f6lster-Holst R, Proksch E, Poblete-Guti\u00e9rrez P. Seborrheic eczema responds more quickly to treatment with pimecrolimus cream than treatment with ketoconazole cream. Exp Dermatol. 2009;18(3):274\u2013333. https:\/\/doi.org\/10.1111\/j.1600-0625.2008.00834.x.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1743_CR159","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/09546630802286993","volume":"20","author":"E Koc","year":"2009","unstructured":"Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009;20(1):4\u20139. https:\/\/doi.org\/10.1080\/09546630802286993.","journal-title":"J Dermatolog Treat"},{"key":"1743_CR160","unstructured":"Queille-Roussel. Efficacy study of a ciclopiroxolamine 1% foam (dc115 gm 02a) versus ciclopiroxolamine 1.5% shampoo (sebiprox\u00ae) in the treatment of moderate seborrheic dermatitis of the scalp. EU Clinical Trials Register. 2009. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-008353-35\/results."},{"issue":"2","key":"1743_CR161","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1473-2165.2009.00431.x","volume":"8","author":"S Seit\u00e9","year":"2009","unstructured":"Seit\u00e9 S, Paries J, Reygagne P, Hamidou Z, Jouanique C, Perez-Pala G, et\u00a0al. A lipohydroxyacid-containing shampoo improves scalp condition and quality of life in patients with seborrheic dermatitis and light-to-moderate scalp psoriasis. J Cosmet Dermatol. 2009;8(2):108\u201313. https:\/\/doi.org\/10.1111\/j.1473-2165.2009.00431.x.","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"1743_CR162","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1473-2165.2009.00460.x","volume":"8","author":"S Seite","year":"2009","unstructured":"Seite S, Rougier A, Talarico S. Randomized study comparing the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis. J Cosmet Dermatol. 2009;8(4):249\u201353. https:\/\/doi.org\/10.1111\/j.1473-2165.2009.00460.x.","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"1743_CR163","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1346-8138.2009.00607.x","volume":"36","author":"H Shin","year":"2009","unstructured":"Shin H, Kwon OS, Won CH, Kim BJ, Lee YW, Choe YB, et\u00a0al. Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study. J Dermatol. 2009;36(3):131\u20137. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00607.x.","journal-title":"J Dermatol"},{"issue":"4","key":"1743_CR164","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/09546630802684692","volume":"20","author":"S Tatlican","year":"2009","unstructured":"Tatlican S, Eren C, Eskioglu F. Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile. J Dermatolog Treat. 2009;20(4):198\u2013202. https:\/\/doi.org\/10.1080\/09546630802684692.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1743_CR165","first-page":"234","volume":"9","author":"ZD Draelos","year":"2010","unstructured":"Draelos ZD. The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. J Drugs Dermatol. 2010;9(3):234\u20136.","journal-title":"J Drugs Dermatol"},{"key":"1743_CR166","unstructured":"Emtestam L. A multicenter, randomised double blind, placebo controlled study of efficacy, safety and tolerability of two topical K40 formulations in adults with Seborrhoeic Dermatitis (SD) of the Scalp. June 3, 2010. https:\/\/clinicaltrials.gov\/study\/NCT01137630."},{"key":"1743_CR167","doi-asserted-by":"publisher","DOI":"10.1002\/central\/CN-01813983\/full","author":"Galderma","year":"2010","unstructured":"Galderma. Efficacy and safety of clobetasol propionate shampoo 0.05% used in association with an antifungal shampoo in the treatment of moderate to severe scalp seborrheic dermatitis\u2014ESCAPE\u2014scalp seborrheic dermatitis. EU Clinical Trials Register. 2010. https:\/\/doi.org\/10.1002\/central\/CN-01813983\/full.","journal-title":"EU Clinical Trials Register"},{"issue":"1","key":"1743_CR168","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/11311160-000000000-00000","volume":"11","author":"MG Ozden","year":"2010","unstructured":"Ozden MG, Nilgun Solak T, Nilsel I, Handan A. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study: an open-label study. Am J Clin Dermatol. 2010;11(1):51\u20134. https:\/\/doi.org\/10.2165\/11311160-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1743_CR169","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4103\/0019-5154.87137","volume":"56","author":"J Das","year":"2011","unstructured":"Das J, Majumdar M, Chakraborty U, Majumdar V, Mazumdar G, Nath J. Oral itraconazole for the treatment of severe seborrhoeic dermatitis. Indian J Dermatol. 2011;56(5):515\u20136. https:\/\/doi.org\/10.4103\/0019-5154.87137.","journal-title":"Indian J Dermatol"},{"issue":"8","key":"1743_CR170","first-page":"895","volume":"10","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Cantrell WC. An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis. J Drugs Dermatol. 2011;10(8):895\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1743_CR171","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1439-0507.2011.02126.x","volume":"55","author":"L Emtestam","year":"2012","unstructured":"Emtestam L, Svensson \u00c5, Rensfeldt K. Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double-blind, randomised, placebo-controlled studies: K301 treatment of seborrhoeic dermatitis. Mycoses. 2012;55(5):393\u2013403. https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02126.x.","journal-title":"Mycoses"},{"issue":"1","key":"1743_CR172","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2133.2011.10269.x","volume":"165","author":"J-P Ortonne","year":"2011","unstructured":"Ortonne J-P, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, et\u00a0al. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0\u00b705% combined with ketoconazole shampoo 2%: a randomized, controlled study: clobetasol shampoo for scalp seborrhoeic dermatitis. Br J Dermatol. 2011;165(1):171\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10269.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1743_CR173","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1468-3083.2011.04187.x","volume":"26","author":"S Wananukul","year":"2012","unstructured":"Wananukul S, Chatproedprai S, Charutragulchai W. Randomized, double-blind, split-side comparison study of moisturizer containing licochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic dermatitis. J Eur Acad Dermatol Venereol. 2012;26(7):894\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04187.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1743_CR174","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2011.11.240","volume":"66","author":"ZD Draelos","year":"2012","unstructured":"Draelos ZD, Feldman SR, Butners V, B AA. Long-term safety of ketoconazole foam 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study. J Am Acad Dermatol. 2012;66(4):56.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1743_CR175","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00403-012-1254-0","volume":"304","author":"S Emre","year":"2012","unstructured":"Emre S, Metin A, Demirseren DD, Akoglu G, Oztekin A, Neselioglu S, et\u00a0al. The association of oxidative stress and disease activity in seborrheic dermatitis. Arch Dermatol Res. 2012;304(9):683\u20137. https:\/\/doi.org\/10.1007\/s00403-012-1254-0.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"1743_CR176","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jaad.2011.02.032","volume":"67","author":"KA Papp","year":"2012","unstructured":"Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol. 2012;67(1):e11\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2011.02.032.","journal-title":"J Am Acad Dermatol"},{"issue":"62","key":"1743_CR177","first-page":"144","volume":"15","author":"R Salmanpoor","year":"2012","unstructured":"Salmanpoor R, Saki N, Mahmoodi G. Liquorice 7% versus selenium sulfide 1% shampoos in the treatment of dandruff: A clinical trial. Iranian Journal of Dermatology. 2012;15(62):144-5.","journal-title":"Iran J Dermatol"},{"key":"1743_CR178","unstructured":"Abbas Z. Efficacy of Itraconazole in the treatment of Seborrheic Dermatitis. Cochrane Central Register of Controlled Trials. 2013. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01882209\/full."},{"issue":"6","key":"1743_CR179","first-page":"477","volume":"18","author":"Y Attarzadeh","year":"2013","unstructured":"Attarzadeh Y, Asilian A, Shahmoradi Z, Adibi N. Comparing the efficacy of Emu oil with clotrimazole and hydrocortisone in the treatment of seborrheic dermatitis: a clinical trial. J Res Med Sci. 2013;18(6):477\u201381.","journal-title":"J Res Med Sci"},{"key":"1743_CR180","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.806765","author":"H Azimi","year":"2013","unstructured":"Azimi H, Golforoushan F, Jaberian M, Talghini S, Goldust M. Efficiency of terbinafine 1% cream in comparison with ketoconazole 2% cream and placebo in patients with facial seborrheic dermatitis. J Dermatolog Treat. 2013. https:\/\/doi.org\/10.3109\/09546634.2013.806765.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1743_CR181","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40257-013-0019-7","volume":"14","author":"A C\u00f6mert","year":"2013","unstructured":"C\u00f6mert A, Akba\u015f B, K\u0131l\u0131\u00e7 EZ, Ak\u0131n \u00d6, G\u00f6k\u00e7e E, G\u00f6ktuna Z, et\u00a0al. Psychiatric comorbidities and alexithymia in patients with seborrheic dermatitis: a questionnaire study in Turkey. Am J Clin Dermatol. 2013;14(4):335\u201342. https:\/\/doi.org\/10.1007\/s40257-013-0019-7.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1743_CR182","first-page":"448","volume":"12","author":"E David","year":"2013","unstructured":"David E, Tanuos H, Sullivan T, Yan A, Kircik LH. A double-blind, placebo-controlled pilot study to estimate the efficacy and tolerability of a nonsteroidal cream for the treatment of cradle cap (seborrheic dermatitis). J Drugs Dermatol. 2013;12(4):448\u201352.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1743_CR183","first-page":"312","volume":"12","author":"C Diehl","year":"2013","unstructured":"Diehl C, Ferrari A. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study. J Drugs Dermatol. 2013;12(3):312\u201315. https:\/\/pubmed.ncbi.nlm.nih.gov\/23545914\/.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1743_CR184","first-page":"173","volume":"59","author":"M Goldust","year":"2013","unstructured":"Goldust M, Rezaee E, Raghifar R. A double blind study of the effectiveness of sertaconazole 2% cream vs. metronidazole 1% gel in the treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(4):173-77. https:\/\/pubmed.ncbi.nlm.nih.gov\/24791343\/.","journal-title":"Ann Parasitol"},{"issue":"1","key":"1743_CR185","first-page":"25","volume":"59","author":"M Goldust","year":"2013","unstructured":"Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013;59(1):25-29. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23829055.","journal-title":"Ann Parasitol"},{"key":"1743_CR186","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.755251","author":"M Goldust","year":"2013","unstructured":"Goldust M, Ranjkesh MR, Amirinia M, Golforoushan F, Rezaee E, Rezazadeh Saatlou MA. Sertaconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2013. https:\/\/doi.org\/10.3109\/09546634.2012.755251.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1743_CR187","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2340\/00015555-1532","volume":"93","author":"T-W Kim","year":"2013","unstructured":"Kim T-W, Mun J-H, Jwa S-W, Song M, Kim H-S, Ko H-C, et\u00a0al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013;93(5):557\u201361. https:\/\/doi.org\/10.2340\/00015555-1532.","journal-title":"Acta Derm Venereol"},{"key":"1743_CR188","unstructured":"Queille-Roussel C. Efficacy and tolerance of V0071 GM 01A in inflammatory seborrhoeic dermatitis of the scalp. EU Clinical Trials Register. 2013. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-007088-25."},{"key":"1743_CR189","unstructured":"Sriraam. Clinical study to evaluate effectiveness, safety and tolerability of Dhathri Hair Care Plus Herbal Oil in comparison with Coconut Oil in the management of hairfall, premature graying of hair and dandruff of the scalp. Cochrane Central Register of Controlled Trials. 2013. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01860071\/full."},{"issue":"1","key":"1743_CR190","doi-asserted-by":"publisher","first-page":"705402","DOI":"10.1155\/2014\/705402","volume":"2014","author":"N Alizadeh","year":"2014","unstructured":"Alizadeh N, Monadi Nori H, Golchi J, Eshkevari SS, Kazemnejad E, Darjani A. Comparison the efficacy of fluconazole and terbinafine in patients with moderate to severe seborrheic dermatitis. Dermatol Res Pract. 2014;2014(1):705402. https:\/\/doi.org\/10.1155\/2014\/705402.","journal-title":"Dermatol Res Pract"},{"issue":"51","key":"1743_CR191","first-page":"26","volume":"13","author":"A Beheshti Roy","year":"2014","unstructured":"Beheshti Roy A, Tavakoli-Far B, Fallah Huseini H, Tousi P, Shafigh N, Rahimzadeh M. Efficacy of Melaleuca alternifolia essential oil in the treatment of facial seborrheic dermatitis: A double-blind, randomized, placebo-controlled clinical trial. Journal of Medicinal Plants. 2014;13(51):26-32. https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-84914675355&partnerID=40&md5=5c9802762e5d21d7328e4ca293a4ae2d.","journal-title":"J Med Plants"},{"issue":"3","key":"1743_CR192","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/09546634.2013.782092","volume":"25","author":"SA Buechner","year":"2014","unstructured":"Buechner SA. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 2014;25(3):226\u201331. https:\/\/doi.org\/10.3109\/09546634.2013.782092.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1743_CR193","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/09546634.2013.814754","volume":"25","author":"G Fabbrocini","year":"2014","unstructured":"Fabbrocini G, Cantelli M, Monfrecola G. Topical nicotinamide for seborrheic dermatitis: an open randomized study. J Dermatolog Treat. 2014;25(3):241\u20135. https:\/\/doi.org\/10.3109\/09546634.2013.814754.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1743_CR194","doi-asserted-by":"publisher","first-page":"733","DOI":"10.5021\/ad.2014.26.6.733","volume":"26","author":"YR Kim","year":"2014","unstructured":"Kim YR, Kim J-H, Shin H-J, Choe YB, Ahn KJ, Lee YW. Clinical evaluation of a new-formula shampoo for scalp seborrheic dermatitis containing extract of Rosa centifolia petals and epigallocatechin gallate: a randomized, double-blind, controlled study. Ann Dermatol. 2014;26(6):733\u20138. https:\/\/doi.org\/10.5021\/ad.2014.26.6.733.","journal-title":"Ann Dermatol"},{"issue":"1","key":"1743_CR195","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jdv.12070","volume":"28","author":"SH Kwon","year":"2014","unstructured":"Kwon SH, Jeong MY, Park KC, Youn SW, Huh CH, Na JI. A new therapeutic option for facial seborrhoeic dermatitis: indole-3-acetic acid photodynamic therapy: indole-3-acetic acid photodynamic therapy in facial seborrhoeic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(1):94\u20139. https:\/\/doi.org\/10.1111\/jdv.12070.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1743_CR196","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13555-014-0047-0","volume":"4","author":"V Turlier","year":"2014","unstructured":"Turlier V, Viode C, Durbise E, Bacquey A, LeJeune O, Oliveira Soares R, et\u00a0al. Clinical and biochemical assessment of maintenance treatment in chronic recurrent seborrheic dermatitis: randomized controlled study. Dermatol Ther (Heidelb). 2014;4(1):43\u201359. https:\/\/doi.org\/10.1007\/s13555-014-0047-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1743_CR197","first-page":"33","volume":"8","author":"F Dall\u2019Oglio","year":"2015","unstructured":"Dall\u2019Oglio F, Tedeschi A, Guardabasso V, Micali G. Evaluation of a topical anti-inflammatory\/antifungal combination cream in mild-to-moderate facial seborrheic dermatitis: An intra-subject controlled trial examining treated vs. Untreated skin utilizing clinical features and erythema-directed digital photography. J Clin Aesthet Dermatol. 2015;8(9):33\u20138. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26430489.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"1743_CR198","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5021\/ad.2015.27.5.523","volume":"27","author":"HO Kim","year":"2015","unstructured":"Kim HO, Yang YS, Ko HC, Kim GM, Cho SH, Seo YJ, et\u00a0al. Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. Ann Dermatol. 2015;27(5):523\u201330. https:\/\/doi.org\/10.5021\/ad.2015.27.5.523.","journal-title":"Ann Dermatol"},{"issue":"3","key":"1743_CR199","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5826\/dpc.0603a04","volume":"6","author":"Z Abbas","year":"2016","unstructured":"Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Dermatol Pract Concept. 2016;6(3):11\u20136. https:\/\/doi.org\/10.5826\/dpc.0603a04.","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"1743_CR200","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijwd.2016.11.008","volume":"3","author":"K Balighi","year":"2017","unstructured":"Balighi K, Ghodsi SZ, Daneshpazhooh M, Ghale-Baghi S, Nasimi M, Azizpour A. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: a double-blind, randomized clinical trial. Int J Womens Dermatol. 2017;3(2):107\u201310. https:\/\/doi.org\/10.1016\/j.ijwd.2016.11.008.","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"1743_CR201","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000439354","volume":"1","author":"F Dall\u2019Oglio","year":"2016","unstructured":"Dall\u2019Oglio F, Lacarrubba F, Verz\u00ec AE, Micali G. Noncorticosteroid combination shampoo versus 1% ketoconazole shampoo for the management of mild-to-moderate seborrheic dermatitis of the scalp: results from a randomized, investigator-single-blind trial using clinical and trichoscopic evaluation. Skin Appendage Disord. 2016;1(3):126\u201330. https:\/\/doi.org\/10.1159\/000439354.","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"1743_CR202","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.5114\/amsad.2016.65075","volume":"1","author":"B Imamoglu","year":"2016","unstructured":"Imamoglu B, Hayta SB, Guner R, Akyol M, Ozcelik S. Metabolic syndrome may be an important comorbidity in patients with seborrheic dermatitis. Arch Med Sci Atheroscler Dis. 2016;1(1):e158\u201361. https:\/\/doi.org\/10.5114\/amsad.2016.65075.","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"14","key":"1743_CR203","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4103\/0366-6999.209895","volume":"130","author":"Q An","year":"2017","unstructured":"An Q, Sun M, Qi R-Q, Zhang L, Zhai J-L, Hong Y-X, et\u00a0al. High Staphylococcus epidermidis colonization and impaired permeability barrier in facial seborrheic dermatitis. Chin Med J (Engl). 2017;130(14):1662\u20139. https:\/\/doi.org\/10.4103\/0366-6999.209895.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"1743_CR204","first-page":"17","volume":"10","author":"D Barak-Shinar","year":"2017","unstructured":"Barak-Shinar D, Del R\u00edo R, Green LJ. Treatment of seborrheic dermatitis using a novel herbal-based cream. J Clin Aesthet Dermatol. 2017;10(4):17\u201323.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1743_CR205","unstructured":"Guo AM. Seborrheic Dermatitis: ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo. Clinicaltrials.gov. 2017. https:\/\/clinicaltrials.gov\/study\/NCT01203189."},{"key":"1743_CR206","unstructured":"Han Y. Anti-microbial, anti-inflammatory treatment of seborrheic dermatitis with single center, researcher blind, randomized controlled study. Cochrane Central Register of Controlled Trials. 2017. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01886551\/full?highlightAbstract=treatment%7Crandomis%7Cblind%7Cstudy%7Cdermat%7Cinflammatory%7Cresearch%7Canti%7Crandom%7Cdermatitis%7Cof%7Cmicrobi%7Cseborrhoeic%7Crandomised%7Cresearcher%7Ccenter%7Ccentr%7Ccentre%7Ccontrol%7Cmicrobial%7Cseborrho%7Ccontrolled%7Csingle%7Cwith%7Cseborrheic%7Cstudi%7Cseborrh%7Cinflammatori%7Csingl%7Crandomized."},{"issue":"1","key":"1743_CR207","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ijd.13408","volume":"56","author":"C de Souza Le\u00e3o Kamamoto","year":"2017","unstructured":"de Souza Le\u00e3o Kamamoto C, Sanudo A, Hassun KM, Bagatin E. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol. 2017;56(1):80\u20135. https:\/\/doi.org\/10.1111\/ijd.13408.","journal-title":"Int J Dermatol"},{"key":"1743_CR208","unstructured":"Sriraam. Clinical Study on Ayurvedic Hair Oil and Shampoo vs Coconut Oil and Regular Shampoo to test on hair fall, dandruff of the scalp, grey hair and split ends. CTRI. 2017. http:\/\/www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=16442."},{"issue":"1","key":"1743_CR209","first-page":"26","volume":"11","author":"D Barak-Shinar","year":"2018","unstructured":"Barak-Shinar D, Green LJ. Scalp seborrheic dermatitis and dandruff therapy using a herbal and zinc pyrithione-based therapy of shampoo and scalp lotion. J Clin Aesthet Dermatol. 2018;11(1):26\u201331.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1743_CR210","unstructured":"Jilani, Fasihuzzaman. Clinical Study of a Topical Unani Formulation for Dandruff in Females. Cochrane Central Register of Controlled Trials. 2018. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01903366\/full."},{"key":"1743_CR211","unstructured":"Maruho. Omiganan BID in patients with facial seborrheic dermatitis. Cochrane Central Register of Controlled Trials. 2018. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01905427\/abstract."},{"key":"1743_CR212","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/CCID.S158428","volume":"11","author":"Y Takagi","year":"2018","unstructured":"Takagi Y, Ning X, Takahashi A, Ishizaki C, Nishizaka T, Kaizu K, et\u00a0al. The efficacy of a pseudo-ceramide and eucalyptus extract containing lotion on dry scalp skin. Clin Cosmet Investig Dermatol. 2018;11:141\u20138. https:\/\/doi.org\/10.2147\/CCID.S158428.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1743_CR213","unstructured":"Yaghoubi SF. Evaluation of effectiveness of betamethasone lotine 0\/1% compared with clotrizone lotion (clotrimazole1% and betamethasone 0\/05%) in patients with seborrheic dermatitis of face and scalp. Cochrane Central Register of Controlled Trials. 2018. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01814436\/full."},{"issue":"1","key":"1743_CR214","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/jocd.12353","volume":"17","author":"J Zhao","year":"2018","unstructured":"Zhao J, Sun W, Zhang C, Wu J, Le Y, Huang C, et\u00a0al. Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis. J Cosmet Dermatol. 2018;17(1):90\u20134. https:\/\/doi.org\/10.1111\/jocd.12353.","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"1743_CR215","first-page":"13","volume":"22","author":"T Agustin","year":"2019","unstructured":"Agustin T, Rahmayunita G, Astriningrum R, Miranda E, Pusponegoro EHD, Widaty S. Quality of life assessment in patients with dandruff and scalp seborrheic dermatitis at a tertiary hospital in Indonesia. Iran J Dermatol. 2019;22(1):13\u20137.","journal-title":"Iran J Dermatol"},{"issue":"5","key":"1743_CR216","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3906\/sag-1906-72","volume":"49","author":"E Akta\u015f Karabay","year":"2019","unstructured":"Akta\u015f Karabay E, Aksu \u00c7erman A. Serum zinc levels in seborrheic dermatitis: a case-control study. Turk J Med Sci. 2019;49(5):1503\u20138. https:\/\/doi.org\/10.3906\/sag-1906-72.","journal-title":"Turk J Med Sci"},{"key":"1743_CR217","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2147\/CCID.S231313","volume":"12","author":"E Campione","year":"2019","unstructured":"Campione E, Mazzilli S, Lanna C, Cosio T, Palumbo V, Cesaroni G, et\u00a0al. The effectiveness of a new topical formulation containing GSH-C4 and hyaluronic acid in seborrheic dermatitis: preliminary results of an exploratory pilot study. Clin Cosmet Investig Dermatol. 2019;12:881\u20135. https:\/\/doi.org\/10.2147\/CCID.S231313.\u00a0","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1743_CR218","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/CCID.S186621","volume":"12","author":"F Dall\u2019Oglio","year":"2019","unstructured":"Dall\u2019Oglio F, Lacarrubba F, Luca M, Boscaglia S, Granger C, Micali G. Clinical and instrumental evaluation of a new topical non-corticosteroid antifungal\/anti-inflammatory\/antiseborrheic combination cream for the treatment of mild-to-moderate facial seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2019;12:103\u20138. https:\/\/doi.org\/10.2147\/CCID.S186621.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"1743_CR219","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1590\/abd1806-4841.20198578","volume":"94","author":"ZGK \u0130slamo\u011flu","year":"2019","unstructured":"\u0130slamo\u011flu ZGK. Second-to-fourth digit ratio and seborrheic dermatitis in males: a cross-sectional study. An Bras Dermatol. 2019;94(3):327\u201330. https:\/\/doi.org\/10.1590\/abd1806-4841.20198578.","journal-title":"An Bras Dermatol"},{"key":"1743_CR220","doi-asserted-by":"publisher","DOI":"10.17966\/JMI.2019.24.1.1","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim J-H, Shin H-J, Lee YW. Clinical and biochemical assessment of new-formula shampoo for scalp seborrheic dermatitis. Taehan Uijinkyun Hakhoe Chi. 2019. https:\/\/doi.org\/10.17966\/JMI.2019.24.1.1.","journal-title":"Taehan Uijinkyun Hakhoe Chi"},{"key":"1743_CR221","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/CCID.S205904","volume":"12","author":"M Puviani","year":"2019","unstructured":"Puviani M, Campione E, Offidani AM, De Grandi R, Bianchi L, Bobyr I, et\u00a0al. Effects of a cream containing 5% hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face. Clin Cosmet Investig Dermatol. 2019;12:285\u201393. https:\/\/doi.org\/10.2147\/CCID.S205904.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1743_CR222","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CCID.S196412","volume":"12","author":"M Sobhan","year":"2019","unstructured":"Sobhan M, Gholampoor G, Firozian F, Mohammadi Y, Mehrpooya M. Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2019;12:267\u201375. https:\/\/doi.org\/10.2147\/CCID.S196412.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"1743_CR223","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3889\/oamjms.2019.056","volume":"7","author":"TN Van","year":"2019","unstructured":"Van TN, Thi NH, Van TH, Van HL, Huu ND, Minh PPT, et\u00a0al. Efficacy of oral itraconazole in the treatment of seborrheic dermatitis in Vietnamese adults patients. Open Access Maced J Med Sci. 2019;7(2):224\u20136. https:\/\/doi.org\/10.3889\/oamjms.2019.056.","journal-title":"Open Access Maced J Med Sci"},{"key":"1743_CR224","doi-asserted-by":"publisher","first-page":"e1875","DOI":"10.6061\/clinics\/2020\/e1875","volume":"75","author":"R-L Gu","year":"2020","unstructured":"Gu R-L, Wang S-Q. Clinical study on treatment of facial seborrheic dermatitis with intense pulsed light combined with 30% supramolecular salicylic acid. Clinics. 2020;75:e1875. https:\/\/doi.org\/10.6061\/clinics\/2020\/e1875.","journal-title":"Clinics"},{"key":"1743_CR225","unstructured":"Farmaceutici. Study to evaluate the efficacy and safety of Nicotinamide DS compared to Ciclopirox olamine at 1% cream in seborrheic dermatitis. Cochrane Central Register of Controlled Trials. October 31, 2021. Accessed March 8, 2026. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02329038\/full."},{"issue":"12","key":"1743_CR226","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1111\/jdv.16673","volume":"34","author":"SM Pe\u00f1a","year":"2020","unstructured":"Pe\u00f1a SM, Oak ASW, Smith AM, Mayo TT, Elewski BE. Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):e809\u201312. https:\/\/doi.org\/10.1111\/jdv.16673.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1743_CR227","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000510896","volume":"6","author":"C Vincenzi","year":"2020","unstructured":"Vincenzi C, Tosti A. Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis. Skin Appendage Disord. 2020;6(6):355\u201361. https:\/\/doi.org\/10.1159\/000510896.","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"1743_CR228","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.18295\/squmj.2018.18.04.015","volume":"18","author":"FB Yap","year":"2018","unstructured":"Yap FB. The role of combination calcipotriol plus betamethasone dipropionate gel in the treatment of moderate-to-severe scalp seborrhoeic dermatitis. Sultan Qaboos Univ Med J. 2018;18(4):e520\u20133. https:\/\/doi.org\/10.18295\/squmj.2018.18.04.015.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"1743_CR229","doi-asserted-by":"publisher","unstructured":"Bolmall C. Efficacy, safety and tolerability of sertaconazole 2% plus zinc pyrithione 1% shampoo vs ketoconazole 2% shampoo in adult patients with dandruff. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2009\/091\/001079 [Internet]. 2021 [cited 2026 Mar 8]; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/https:\/\/doi.org\/10.1002\/central\/CN-01876246\/abstract.","DOI":"10.1002\/central\/CN-01876246\/abstract"},{"key":"1743_CR230","unstructured":"Chakkavittumrong P. A double-blind split-face randomized controlled trial of the efficacy of 2% Curcuma aeruginosa Roxb. extract-containing cream compared with 2% ketoconazole cream in facial seborrheic dermatitis. Cochrane Central Register of Controlled Trials. May 31, 2021. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02255818\/full."},{"issue":"1","key":"1743_CR231","doi-asserted-by":"publisher","first-page":"6623271","DOI":"10.1155\/2021\/6623271","volume":"2021","author":"S Rahimi","year":"2021","unstructured":"Rahimi S, Nemati N, Shafaei-Tonekaboni SS. Serum levels of 25-hydroxyvitamin D in patients with seborrheic dermatitis: a case-control study. Dermatol Res Pract. 2021;2021(1):6623271. https:\/\/doi.org\/10.1155\/2021\/6623271.","journal-title":"Dermatol Res Pract"},{"key":"1743_CR232","unstructured":"Sepaskhah M. Comparison of the efficacy of ivermectin cream and ketoconazole cream in treatment of facial seborrheic dermatitis. Cochrane Central Register of Controlled Trials. October 31, 2021. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02329643\/abstract."},{"key":"1743_CR233","unstructured":"Sonawane. Comparative Study of 2 Anti-Dandruff shampoos, in patients with dandruff. Cochrane Central Register of Controlled Trials. October 31, 2021. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02328170\/full."},{"issue":"5","key":"1743_CR234","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/1751-7915.13897","volume":"14","author":"R Yu","year":"2021","unstructured":"Yu R, Lin Q, Zhai Y, Mao Y, Li K, Gao Y, et\u00a0al. Recombinant human thymosin beta-4 (rhT\u03b24) improved scalp condition and microbiome homeostasis in seborrheic dermatitis. Microb Biotechnol. 2021;14(5):2152\u201363. https:\/\/doi.org\/10.1111\/1751-7915.13897.","journal-title":"Microb Biotechnol"},{"issue":"3","key":"1743_CR235","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.51253\/pafmj.v72i3.7430","volume":"72","author":"M Rizwan","year":"2022","unstructured":"Rizwan M, Ali A, Ahmad N, Tahir M. Topical betamethasone valerate 0.1% W\/V vs. topical ketoconazole 2% W\/V: a comparison of efficacy in patients of seborrheic dermatitis. Pak Armed Force Med J. 2022;72(3):1082\u20135. https:\/\/doi.org\/10.51253\/pafmj.v72i3.7430.","journal-title":"Pak Armed Force Med J"},{"issue":"5","key":"1743_CR236","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/ced.15067","volume":"47","author":"M Azizzadeh","year":"2022","unstructured":"Azizzadeh M, Pahlevan D, Bagheri B. The efficacy and safety of pimecrolimus 1% cream vs. sertaconazole 2% cream in the treatment of patients with facial seborrhoeic dermatitis: a randomized blinded trial. Clin Exp Dermatol. 2022;47(5):926\u201331. https:\/\/doi.org\/10.1111\/ced.15067.","journal-title":"Clin Exp Dermatol"},{"key":"1743_CR237","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/CCID.S344807","volume":"15","author":"C Cort\u00e9s-Correa","year":"2022","unstructured":"Cort\u00e9s-Correa C, Piquero-Casals J, Chaparro-Reyes D, Garr\u00e9 Contreras A, Granger C, Pe\u00f1aranda-Contreras E. Facial seborrheic dermatitis in HIV-seropositive patients: evaluation of the efficacy and safety of a non-steroidal cream containing piroctone olamine, biosaccharide gum-2 and stearyl glycyrrhetinate - a case series. Clin Cosmet Investig Dermatol. 2022;15:483\u20138. https:\/\/doi.org\/10.2147\/CCID.S344807.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"1743_CR238","doi-asserted-by":"publisher","first-page":"419","DOI":"10.23736\/S2784-8671.22.07246-2","volume":"157","author":"G Damiani","year":"2022","unstructured":"Damiani G, Finelli R, Kridin K, Pacifico A, Buja A, Bragazzi NL, et\u00a0al. Masks trigger facial seborrheic dermatitis and psoriasis: evidence from a multicenter, case-control study during COVID-19 pandemic. Ital J Dermatol Venerol. 2022;157(5):419\u201323. https:\/\/doi.org\/10.23736\/S2784-8671.22.07246-2.","journal-title":"Ital J Dermatol Venerol"},{"issue":"5","key":"1743_CR239","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/jocd.14362","volume":"21","author":"P Massiot","year":"2022","unstructured":"Massiot P, Clavaud C, Thomas M, Ott A, Gu\u00e9niche A, Panhard S, et\u00a0al. Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole. J Cosmet Dermatol. 2022;21(5):2215\u201325. https:\/\/doi.org\/10.1111\/jocd.14362.","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"1743_CR240","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1111\/jocd.14719","volume":"21","author":"Z Metin","year":"2022","unstructured":"Metin Z, Durmaz K. Clinical study: is seborrheic dermatitis associated with systemic inflammation? J Cosmet Dermatol. 2022;21(9):4087\u20138. https:\/\/doi.org\/10.1111\/jocd.14719.","journal-title":"J Cosmet Dermatol"},{"key":"1743_CR241","unstructured":"Sadati MS. Comparison of the efficacy of rosemary lotion and ketoconazole lotion in treatment of seborrheic dermatitis. Cochrane Central Register of Controlled Trials. November 30, 2022. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02499253\/abstract."},{"issue":"3","key":"1743_CR242","doi-asserted-by":"publisher","first-page":"362","DOI":"10.5472\/marumj.1195298","volume":"35","author":"E Sarac","year":"2022","unstructured":"Sarac E, Kocat\u00fcrk E. Relationship between disease severity, perceived stress, and depression in patients with seborrheic dermatitis. Marmara Med J. 2022;35(3):362\u20136. https:\/\/doi.org\/10.5472\/marumj.1195298.","journal-title":"Marmara Med J"},{"issue":"6","key":"1743_CR243","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3988\/jcn.2022.18.6.628","volume":"18","author":"S Tomic","year":"2022","unstructured":"Tomic S, Kuric I, Kuric TG, Popovic Z, Kragujevic J, Zubonja TM, et\u00a0al. Seborrheic dermatitis is related to motor symptoms in Parkinson\u2019s Disease. J Clin Neurol. 2022;18(6):628\u201334. https:\/\/doi.org\/10.3988\/jcn.2022.18.6.628.","journal-title":"J Clin Neurol"},{"issue":"10","key":"1743_CR244","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1111\/jocd.14984","volume":"21","author":"M Tosun","year":"2022","unstructured":"Tosun M, Yasak G\u00fcner R, Akyol M. Investigation of the relationship between inflammatory blood parameters and seborrheic dermatitis. J Cosmet Dermatol. 2022;21(10):5111\u20135. https:\/\/doi.org\/10.1111\/jocd.14984.","journal-title":"J Cosmet Dermatol"},{"issue":"8","key":"1743_CR245","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1111\/jocd.14623","volume":"21","author":"H-C Wang","year":"2022","unstructured":"Wang H-C, Wang C-S, Hsieh S-C, Hung Y-T, Chen H-H. Evaluation of a new-formula shampoo containing 6% glycyrrhetinic acid complex for scalp seborrheic dermatitis: a pilot study. J Cosmet Dermatol. 2022;21(8):3423\u201330. https:\/\/doi.org\/10.1111\/jocd.14623.","journal-title":"J Cosmet Dermatol"},{"issue":"10","key":"1743_CR246","doi-asserted-by":"publisher","first-page":"e13478","DOI":"10.1111\/srt.13478","volume":"29","author":"AS Bazargan","year":"2023","unstructured":"Bazargan AS, Tabavar A, Roohaninasab M, Ali ZN, Tavana Z, Montazeri SSM, et\u00a0al. Evaluation of the effect of botulinum toxin injection in aggravating or improving seborrheic dermatitis symptoms: a prospective, single-arm clinical trial. Skin Res Technol. 2023;29(10):e13478. https:\/\/doi.org\/10.1111\/srt.13478.","journal-title":"Skin Res Technol"},{"issue":"5","key":"1743_CR247","doi-asserted-by":"publisher","first-page":"748","DOI":"10.25259\/IJDVL_319_2022","volume":"89","author":"H Thi Thu Do","year":"2023","unstructured":"Thi Thu Do H, Van Le T, Kanekura T. Comparison of oral itraconazole given for two days plus topical tacrolimus versus topical tacrolimus for maintenance treatment of seborrheic dermatitis in Vietnam. Indian J Dermatol Venereol Leprol. 2023;89(5):748\u201350. https:\/\/doi.org\/10.25259\/IJDVL_319_2022.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"1743_CR248","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1111\/jocd.15957","volume":"22","author":"R Kapoor","year":"2023","unstructured":"Kapoor R, Shome D, Doshi K, Patel G, Tandel H, Kumar V. A newer approach in the treatment of seborrheic dermatitis with QR678\u00ae and QR678 Neo\u00ae-a prospective pilot study. J Cosmet Dermatol. 2023;22(11):3078\u201387. https:\/\/doi.org\/10.1111\/jocd.15957.","journal-title":"J Cosmet Dermatol"},{"key":"1743_CR249","unstructured":"Kumtornrut C. A randomized controlled study of efficacy of topical non-steroidal anti- inflammatory cream in treating mild to moderate seborrheic dermatitis in Thai population. Cochrane Central Register of Controlled Trials. August 31, 2023. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02592111\/full."},{"issue":"1","key":"1743_CR250","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1684\/ejd.2023.4401","volume":"33","author":"P Massiot","year":"2023","unstructured":"Massiot P, Reygagne P, Chagnoleau C, Kanoun-Copy L, Pouradier F, Loussouarn G, et\u00a0al. Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid\/salicylic acid. Eur J Dermatol. 2023;33(1):13\u20138. https:\/\/doi.org\/10.1684\/ejd.2023.4401.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"1743_CR251","first-page":"271","volume":"10","author":"A Ozgul","year":"2023","unstructured":"Ozgul A, Altunisik N, Turkmen D, Sener S. The relationship between seborrheic dermatitis and body composition parameters. Northern Clinics of \u0130stanbul. 2023;10(2):271\u20136.","journal-title":"Northern Clinics of \u0130stanbul"},{"issue":"18","key":"1743_CR252","doi-asserted-by":"publisher","first-page":"14315","DOI":"10.3390\/ijms241814315","volume":"24","author":"J Rousel","year":"2023","unstructured":"Rousel J, Saghari M, Pagan L, N\u0103d\u0103ban A, Gambrah T, Theelen B, et\u00a0al. Treatment with the topical antimicrobial peptide omiganan in mild-to-moderate facial seborrheic dermatitis versus ketoconazole and placebo: results of a randomized controlled proof-of-concept trial. Int J Mol Sci. 2023;24(18):14315. https:\/\/doi.org\/10.3390\/ijms241814315.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1743_CR253","doi-asserted-by":"publisher","first-page":"142","DOI":"10.18231\/j.ijced.2023.026","volume":"9","author":"M Khalse","year":"2023","unstructured":"Khalse M, Sharma A, Pandey A, Parekar R. Efficacy of luliconazole combination shampoo in patients with seborrheic dermatitis. IP Indian J Clin Exp Dermatol. 2023;9(3):142\u20136. https:\/\/doi.org\/10.18231\/j.ijced.2023.026.","journal-title":"IP Indian J Clin Exp Dermatol"},{"issue":"4","key":"1743_CR254","doi-asserted-by":"publisher","first-page":"704","DOI":"10.15584\/ejcem.2023.4.3","volume":"21","author":"V Vysochanska","year":"2023","unstructured":"Vysochanska V, Koval G. Plasma level of beta endorphin in seborrheic dermatitis patients. Eur J Clin Exp Med. 2023;21(4):704\u201310.","journal-title":"Eur J Clin Exp Med"},{"issue":"6","key":"1743_CR255","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.36740\/WLek202306107","volume":"76","author":"V Vysochanska","year":"2023","unstructured":"Vysochanska V, Koval G. Malassezia colonization correlates with the severity of seborrheic dermatitis. Wiad Lek. 2023;76(6):1371\u20137. https:\/\/doi.org\/10.36740\/WLek202306107.","journal-title":"Wiad Lek"},{"issue":"6","key":"1743_CR256","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/ijd.16582","volume":"62","author":"Z Yanfei","year":"2023","unstructured":"Yanfei Z, Xiaoying N, Dingwei Z, Wei W, Jianwen R. Efficacy and safety of oral isotretinoin in the treatment of moderate to severe seborrheic dermatitis: a retrospective study. Int J Dermatol. 2023;62(6):759\u201363. https:\/\/doi.org\/10.1111\/ijd.16582.","journal-title":"Int J Dermatol"},{"key":"1743_CR257","unstructured":"Dong Y. Clinical efficacy and safety study of Shenbai lotion in the treatment of mild to moderate seborrheic dermatitis on the scalp. Cochrane Central Register of Controlled Trials. 2023. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02652388\/abstract."},{"issue":"11","key":"1743_CR258","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1111\/jocd.15818","volume":"22","author":"F Zhang","year":"2023","unstructured":"Zhang F, Li Y-H, Ren W, Li S-R, Chen Y-C. Clinical efficacy of a combination treatment of traditional Chinese medicine for scalp seborrheic dermatitis. J Cosmet Dermatol. 2023;22(11):3072\u20137. https:\/\/doi.org\/10.1111\/jocd.15818.","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"1743_CR259","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamadermatol.2023.0846","volume":"159","author":"MJ Zirwas","year":"2023","unstructured":"Zirwas MJ, Draelos ZD, DuBois J, Kircik LH, Moore AY, Stein Gold L, et\u00a0al. Efficacy of roflumilast foam, 0.3%, in patients with seborrheic dermatitis: a double-blind, vehicle-controlled phase 2a randomized clinical trial. JAMA Dermatol. 2023;159(6):613\u201320. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0846.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1743_CR260","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000539209","volume":"10","author":"V Barbosa","year":"2024","unstructured":"Barbosa V, Melo DF, Va\u00f1\u00f3-Galv\u00e1n S, Lutchmanen-Kolanthan V, Sant\u2019Anna B, Leclerc-Mercier S, et\u00a0al. A comparative randomized clinical study assessing the efficacy of a 1% selenium disulfide-based shampoo versus 2% ketoconazole shampoo in subjects with moderate to severe scalp seborrheic dermatitis. Skin Appendage Disord. 2024;10(6):497\u2013504. https:\/\/doi.org\/10.1159\/000539209.","journal-title":"Skin Appendage Disord"},{"issue":"5","key":"1743_CR261","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","volume":"90","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, et\u00a0al. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024;90(5):986\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.065.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1743_CR262","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/DSS.0000000000003960","volume":"50","author":"YG Choi","year":"2024","unstructured":"Choi YG, Kim SY, Kim JS, Choi Y-J, Kim W-S. Efficacy and safety of precision cryotherapy to treat seborrheic dermatitis of the scalp. Dermatol Surg. 2024;50(1):47\u201347. https:\/\/doi.org\/10.1097\/DSS.0000000000003960.","journal-title":"Dermatol Surg"},{"key":"1743_CR263","unstructured":"Kalra. Homoeopathic vs conventional treatment of Seborrheic dermatitis. Cochrane Central Register of Controlled Trials. 2024. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02674301\/full."},{"issue":"1","key":"1743_CR264","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1038\/s41598-024-53016-0","volume":"14","author":"M Truglio","year":"2024","unstructured":"Truglio M, Sivori F, Cavallo I, Abril E, Licursi V, Fabrizio G, et\u00a0al. Modulating the skin mycobiome-bacteriome and treating seborrheic dermatitis with a probiotic-enriched oily suspension. Sci Rep. 2024;14(1):2722. https:\/\/doi.org\/10.1038\/s41598-024-53016-0.","journal-title":"Sci Rep"},{"key":"1743_CR265","unstructured":"Ungar B. PDE4 inhibition in seborrheic dermatitis and papulopustular rosacea. Cochrane Central Register of Controlled Trials. 2024. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02594297\/full."},{"issue":"1","key":"1743_CR266","doi-asserted-by":"publisher","first-page":"e49965","DOI":"10.2196\/49965","volume":"7","author":"I Weber","year":"2024","unstructured":"Weber I, Zagona-Prizio C, Sivesind TE, Adelman M, Szeto MD, Liu Y, et\u00a0al. Oral cannabidiol for seborrheic dermatitis in patients with Parkinson disease: randomized clinical trial. JMIR Dermatol. 2024;7(1):e49965. https:\/\/doi.org\/10.2196\/49965.","journal-title":"JMIR Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01743-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:03:11Z","timestamp":1780588991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":266,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01743-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Argenx, Astria Therapeutics, Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Forte Biosciences, Galderma, Genentech, GSK, Incyte, Imagene Bio Inc., Johnson & Johnson, Kenvue, Kowa Pharmaceuticals America, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Nia Health, Novartis, Opsidio, Organon, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, SUN Pharma, Takeda, TRex Bio, UCB, Zai Lab. Raj Chovatiya is also an Editorial Board member of Dermatology and Therapy. Raj Chovatiya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Sophia A Mense, Theresa Hopkins, Carmen Li, Jiaqi Chen, Sawyeh Maher, Meredith Polaskey, and Christy H. Chang have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}